Stable suppression of tumorigenicity by virus-mediated RNA interference.

By T. Brummelkamp, René Bernards, Reuven Agami. Cancer Cell, 2002

1,221 citations recorded by the source corpus.

Subfields: Animal Science and Zoology, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/55689eec016d1479868b378a9162fa67af0d9fd1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Animal Science and Zoology

1. J. Kurreck
2. René Bernards
3. W. Kaelin
4. P. Higgins
5. D. Peeper
6. R. Kortlever
7. B. Rowland
8. John J. Rossi

In Genetics

1. J. Kurreck
2. René Bernards
3. W. Kaelin
4. D. Peeper
5. P. Higgins
6. R. Kortlever
7. B. Rowland
8. John J. Rossi

In Molecular Biology

1. J. Kurreck
2. Jerry M. Adams
3. John J. Rossi
4. R. Weinberg
5. W. Kaelin
6. René Bernards
7. K. Helin
8. Suzanne Cory

Citations in the corpus

• Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. (2005, background): “Therefore, most studies using siRNA in vivo involve manipulation of gene expression in a cell line before introduction into an animal model (6, 7) or incorporation of siRNA into a viral vector (8, 9).”
• The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. (2006, methodology): “Retroviral vectors for RNA interference were constructed by ligating annealed oligonucleotides encoding short hairpin sequences into the pRetroSuper vector (Brummelkamp et al., 2002).”
• Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth (2003, methodology): “The resulting duplex oligonucleotides were phosphorylated with T4 polynucleotide kinase (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer’s protocol and ligated into pRETRO-SUPER vector (Brummelkamp et al. 2002) cut with BglII and HindIII.”
• Antisense technologies. Improvement through novel chemical modifications. (2003, methodology): “A retroviral vector was used to deliver siRNA that inhibited the carcinogenic K-ras allele in human pancreatic tumor cells [130].”
• The promises and pitfalls of RNA-interference-based therapeutics (2009, neutral): “For example, it was shown that downregulation of an activated Ras oncogene by a lentiviral-delivered shRNA resulted in suppression of tumour growth in mic”
• Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity (2004, methodology): “This sequence works efficiently in both transient transfection as doublestranded RNA and in the retroviral vector pRetroSuper (pRS) (Brummelkamp et al, 2002).”
• Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence (2006, positive): “To investigate the role of PAI-1 in replicative senescence, two independent retroviral vectors were generated that targeted murine PAI-1 for suppression through RNA”
• KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer (2018, background): “RNA suppression studies in PDAC cell lines showed the strong requirement for tumorigenic growth (Brummelkamp et al. 2002; Lim and Counter 2005).”
• Senescence impairs successful reprogramming to pluripotent stem cells. (2009, methodology): “, 2004), as well as E6, E7, E6/E7, plasmids; HRAS V12, and plasmid for expression of a shRNA targeting p53 (pRS-shp53) have been described before (Acosta et al., 2008; Brummelkamp et al., 2002).”
• Receptor for RACK1 Mediates Activation of JNK by Protein Kinase C (2005, methodology): “To construct pRS-RACK1, the oligos were annealed and ligated into BglII and HindIII sites of pRetroSuper vector (pRS, Brummelkamp et al., 2002).”
• The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene (2005, methodology): “To test this, we used a short hairpin RNA (shRNA) retroviral vector (pRetroSUPER”
• Lentivirus-delivered stable gene silencing by RNAi in primary cells. (2003, methodology): “Lentihair-slLUC and Lentihair-slGFP1 were produced by cotransfection with pHCMVG (Burns et al. 1993) and pCMV R8.”